Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 770-773

  Kosowska Shick, Klaudia ^a   Credito, Kim L ^a   Pankuch, Glenn A ^a   DeWasse, Bonifacio ^a   McGhee, Pamela ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DRUG CROSS REACTIVITY; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; PROTEIN MOTIF; STREPTOCOCCUS PNEUMONIAE;

AMIDOHYDROLASES; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PNEUMOCOCCAL INFECTIONS; SPECIES SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 33846573709     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01150-06     Document Type: Article

References (18)

1. Browne, F. A., C. Clark, B. Bozdogan, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2002. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin. Int. J. Antimicrob. Agents 20:93-99.
2. Canu, A., B. Malbruny, M. Coquemont, T. A. Davies, P. C. Appelbaum, and R. Leclercq. 2002. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:125-131.
3. Craig, W. A., and S. Gudmondsson. 1996. Postantibiotic effect, p. 265-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, MD.
4. Ednie, L. M., G. Pankuch, and P. C. Appelbaum. 2004. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared to other agents. Antimicrob. Agents Chemother. 48:4027-4032.
5. Fritsche, T. R., H. S. Sader, R. Cleeland, and R. N. Jones. 2005. Comparative antimicrobial characteristics of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antmicrob. Agents Chemother. 49:1468-1476.
6. Havarstein, L. S., G. Coomaraswamy, and D. A. Morrison. 1995. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc. Natl. Acad. Sci. USA 92:11140-11144.
7. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
8. Jones, R. N., T. R. Fritsche, and H. S. Sader. 2004. Antimicrobial spectrum and activity of NVP-PDF 713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49:63-65.
9. Jones, R. N., G. J. Moet, H. S. Sader, and T. R. Fritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP-PDF 713) against oxazolidinone-resistant or streptogramin-resistant gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.
10. Margolis, P., C. Hackbarth, S. Lopez, M. Maniar, W. Wang, Z. Yuan, R. White, and J. Trias. 2001. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. 45:2432-2435.
11. Matic, V., K. Kosowska, B. Bozdogan, L. M. Kelly, K. Smith, L. M. Ednie, G. Lin, K. L. Credito, C. L. Clark, P. McGhee, G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum. 2004. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Antimicrob. Agents Chemother. 48:4103-4112.
12. Meinnel, T., C. Lazennec, S. Villoing, and S. Blanquet. 1997. Structure-function relationships within the peptide deformylase family. Evidence for a conserved architecture of the active site involving three conserved motifs and a metal ion. J. Mol. Biol. 267:749-761.
13. Nagai, K., T. A. Davies, G. A. Pankuch, B. E. DeWasse, M. R. Jacobs, and P. C. Appelbaum. 2000. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2740-2746.
14. National Committee for Clinical Laboratory Standards. 2005. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed.; approved standard. NCCLS publication no. M7-A7. National Committee for Clinical Laboratory Standards, Wayne, PA.
15. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
16. Pankuch, G. A., S. A. Juenemann, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 1998. In vitro selection of resistance to four β-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2914-2918.
17. Tait-Kamradt, A., T. Davies, P. C. Appelbaum, F. Depardieu, P. Courvalin, J. Petitpas, L. Wondrack, A. Walker, M. R. Jacobs, and J. Sutcliffe. 2000. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob. Agents Chemother. 44:3395-3401.
18. Watters, A. A., R. N. Jones, J. A. Leeds, G. Denys, H. S. Sader, and T. R. Fritsche. 2006. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J. Antimicrob. Chemother. 57:914-923.